STOCK TITAN

Uranium Royalty (UROY) 10-Q Filings

UROY NASDAQ

Here are the 10-Q quarterly reports from Uranium Royalty Corp. (UROY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow UROY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UROY filings page.

Rhea-AI Summary

Uranium Royalty Corp. (UROY) reported a sharp step‑up in scale and complexity for the quarter ended July 31, 2026, driven by the Sweetwater acquisition and large uranium sales. Sales of uranium inventory rose to $51.0 million on 593,255 pounds sold, generating operating income of $16.4 million and net income of $16.3 million versus $1.0 million a year earlier. Royalty revenue increased to $0.7 million, largely from the newly acquired Sweetwater soda ash royalty portfolio.

The Sweetwater transaction added $441.96 million of land and $1.30 billion of mineral properties and interests, funded by $964.3 million in total consideration, including $330 million cash, common shares and $22.6 million of mandatorily redeemable preferred stock. The deal also brought in substantial obligations, notably $535.7 million of long‑term debt (plus $17.1 million current portion), $31.4 million of advanced minimum royalties and a $40.0 million bridge loan under a new revolving credit facility.

At quarter‑end, cash was $54.1 million and restricted cash $49.5 million, but working capital stood at a $17.3 million deficit. Management disclosed that the required repayment of the $40.0 million bridge loan by January 31, 2027 and other obligations, together with reliance on equity financing, royalty cash flows and potential asset sales, create substantial doubt about the company’s ability to continue as a going concern; the board concluded its plans do not currently alleviate this doubt.